Teleflex Inc

Teleflex Inc(TFX)股票分析

$136.290

-0.286 (-0.21%)收盤時

Loading chart…
最高
137.550
開盤
136.450
成交量加權均價
136.28
成交量
505.10K
市值
9.76B
最低
135.000
成交金額
68.84M
企業價值/稅息折舊攤銷前利潤(TTM)
21.64

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters.

AI 分析 of Teleflex Inc (TFX)

買進

Teleflex Inc is a good buy right now due to its current price of $136.29, which is below the analyst price target of $158, indicating a potential upside of 15.9%. Additionally, the stock has shown a strong 20-day change of +11.65%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, indicating potential financial leverage concerns.

分析師評級(12)

-0.07% 下跌空間
買進
10 買進
2 持有
0 賣出
目前: 136.29
最低
122.00
平均
136.20
最高
155.00

BofA

2026-09-28

目標價

$158

買進

UBS

2026-08-11

目標價

$158

中性

Truist

2026-08-10

目標價

$150

持有

Raymond James

2026-08-07

目標價

$155

優於大盤

Needham

2026-07-31

目標價

$159

買進

估值指標

Teleflex Inc(TFX)目前預期本益比為 11.01,5 年平均預期本益比為 15.72。

預期本益比

合理
5 年均值 P/E
15.72
目前P/E
11.01
高估
20.75
低估
10.70

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
16.05
目前EV/EBITDA
21.64
高估
26.36
低估
5.75

預期股價營收比

合理
5 年均值 P/S
3.21
目前P/S
2.45
高估
4.34
低估
2.08

Alphio AI 對 TFX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TFX

$155.14

情境價格

基

基準

基準 · 50%TFX

$141.18

情境價格

悲

悲觀

悲觀 · 25%TFX

$135.32

情境價格

持有 TFX 的大戶

A

Abrams Bison Investments, L.L.C.

+ 持有TFX

+2.03%

3個月報酬率

H

Heartland Advisors, Inc.

+ 持有TFX

+1.90%

3個月報酬率

T

The Baupost Group, L.L.C.

+ 持有TFX

+0.90%

3個月報酬率

C

Cooke & Bieler, L.P.

+ 持有TFX

-0.99%

3個月報酬率

S

Sessa Capital IM, L.P.

+ 持有TFX

-11.20%

3個月報酬率

事件時間軸

2026-10-22 (ET)

07:00:00

Teleflex Receives FDA Breakthrough Device Designation for Freesolve

2026-10-12 (ET)

07:00:00

Teleflex Completes Patient Enrollment in BIOMAG-LL Clinical Study

2026-09-29 (ET)

07:00:00

Teleflex Study Shows Arrowg+ard Technology Reduces CLABSI Risk by 70%

2026-09-28 (ET)

17:00:00

Nyxoah Appoints Liam Kelly as CEO

09:00:00

Stock Futures Decline Due to Rising Oil Prices and Treasury Yields

資訊

TFX 常見問題 —— 由 Alphio AI 解答

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Teleflex Inc is a good buy right now due to its current price of $136.29, which is below the analyst price target of $158, indicating a potential upside of 15.9%. Additionally, the stock has shown a strong 20-day change of +11.65%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, indicating potential financial leverage concerns.

12 analysts cover TFX: 10 rate it Buy, 2 Hold and 0 Sell. The average price target is 136.20.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易